News

  • Crossject reports positive results from bioequivalence study with neddle-free ZENEO® Methotrexate

    Crossject, the creator of ZENEO®, a needle-free injection system, announces the similarity betweeen the ZENEO® Methotrexate neddle-free injection system and the current injectable formulation. 

    Read more
  • Crossject Appoints Henri de Parseval as Supply Chain Director

    CROSSJECT, the creator of ZENEO®, the world’s most advanced needle-free injection system, announces the appointment of Henri de Parseval as the Company’s first Supply Chain Director. 

    Read more

Events

  • 08/04/2014

    Crossject will be present at Drug Delivery Partnership Europe

    Meet us in Hamburg, September 17th and 18th to Drug Delivery Partnership Europe.
    Contact Tim Muller: tm@scientex.eu or t.muller@crossject.com  / Mobile +33 (0)645523540 / +33(0)602510791 / skype id: timotheemuller

    Read more
  • 08/04/2014

    Crossject will be present at Large and Mid Cap Event 2014

    Meet us in Large and Mid Cap Event 2014 will take place in Paris, October 2nd and 3rd.
    This forum will bring together almost 120 companies listed on NYSE Euronext’s European market and over 400 institutional investors from around Europe.
    Contact Tim Muller:  tm@scientex.eu or t.muller@crossject.com  / Mobile +33 (0)645523540 / +33(0)602510791 / skype id: timotheemuller

    Read more

video

Discover our needle-free self injectable solution

The desire for safer and more user-friendly injection device to prevent needle-stick injuries...

more videos